Press releases

and Paris (May 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month sub-population data from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites...

and Paris (May 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month results from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites in Europe,...

(May 24, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has completed enrollment in ARRIVE, a peri-approval registry. ARRIVE was designed to collect and analyze...

(May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast an analyst meeting it is hosting on Wednesday, May 26, in conjunction with the Paris Course on Revascularization (PCR), the...

and New Orleans, LA (May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced sub-population data from a 12-month, 117-patient study of the Enteryx procedure for patients...

and New Orleans, LA (May 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced clinical trial data supporting the safety and effectiveness of the Enteryx procedure in relieving...

(May 17, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Banc of America Securities Health Care Conference 2004, which is being held May 19-21 in Las Vegas....

(May 4, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for...

(May 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for...

(April 30, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Unplugged Conference, which is being held May 5-7 in Miami. On...